← Back to home

SYSTEMIC SCLEROSIS CUTANEOUS LUPUS E MYOPATHIES SYSTEMIC LUPUS ERYTHEMATOSUS

Clinical trials for SYSTEMIC SCLEROSIS CUTANEOUS LUPUS E MYOPATHIES SYSTEMIC LUPUS ERYTHEMATOSUS explained in plain language.

Never miss a new study

Get alerted when new SYSTEMIC SCLEROSIS CUTANEOUS LUPUS E MYOPATHIES SYSTEMIC LUPUS ERYTHEMATOSUS trials appear

Sign up with your email to follow new studies for SYSTEMIC SCLEROSIS CUTANEOUS LUPUS E MYOPATHIES SYSTEMIC LUPUS ERYTHEMATOSUS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Continued anifrolumab treatment studied for lupus and related diseases

Disease control Not yet recruiting

This study offers continued access to anifrolumab (Saphnelo) for people with systemic lupus erythematosus, systemic sclerosis, or myopathies who completed a prior anifrolumab trial and are still benefiting from the drug. Participants receive the same treatment as before, while re…

Matched conditions: SYSTEMIC SCLEROSIS CUTANEOUS LUPUS E MYOPATHIES SYSTEMIC LUPUS ERYTHEMATOSUS

Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control

Last updated Jul 11, 2026 00:00 UTC

SYSTEMIC SCLEROSIS CUTANEOUS LUPUS E MYOPATHIES SYSTEMIC LUPUS ERYTHEMATOSUS

Get alerted when new SYSTEMIC SCLEROSIS CUTANEOUS LUPUS E MYOPATHIES SYSTEMIC LUPUS ERYTHEMATOSUS trials appear

Continued anifrolumab treatment studied for lupus and related diseases